Literature DB >> 21950692

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma.

Elisabeth Grey-Davies, Jennifer L Bosworth, Kevin D Boyd, Caroline Ebdon, Radovan Saso, Dipti Chitnavis, Jane E Mercieca, Gareth J Morgan, Faith E Davies.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21950692     DOI: 10.1111/j.1365-2141.2011.08887.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

1.  Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Authors:  Heinz Ludwig; Hedwig Kasparu; Clemens Leitgeb; Elisabeth Rauch; Werner Linkesch; Niklas Zojer; Richard Greil; Adelheid Seebacher; Ludek Pour; Adalbert Weißmann; Zdenek Adam
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

2.  Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.

Authors:  Elisabeth Stöhr; Frederic Carsten Schmeel; Leonard Christopher Schmeel; Mathias Hänel; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-09       Impact factor: 4.553

Review 3.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

4.  Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).

Authors:  Juliane Beck; Andreas Schwarzer; Dietrich Gläser; Lars-Olof Mügge; Jens Uhlig; Simone Heyn; Brigitte Kragl; Martin Mohren; Franz Albert Hoffmann; Thoralf Lange; Thomas Schliwa; Thomas Zehrfeld; Cornelia Becker; Ute Kreibich; Cornelia Winkelmann; Thomas Edelmann; Marc Andrea; Marius Bill; Madlen Jentzsch; Sebastian Schwind; Dietger Niederwieser; Wolfram Pönisch
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-21       Impact factor: 4.553

Review 5.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors:  E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

Review 6.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

7.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Authors:  Tomer M Mark; Whitney Reid; Ruben Niesvizky; Usama Gergis; Roger Pearse; Sebastian Mayer; June Greenberg; Morton Coleman; Koen Van Besien; Tsiporah Shore
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-20       Impact factor: 5.742

8.  Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Authors:  Wolfram Pönisch; Malvina Bourgeois; Barbara Moll; Simone Heyn; Nadja Jäkel; Ina Wagner; Robert Rohrberg; Hans-Jürgen Hurtz; Marion Schmalfeld; Michael Aßmann; Thomas Edelmann; Martin Mohren; Franz Albert Hoffmann; Cornelia Becker; Andreas Schwarzer; Uta Schönfelder; Thomas Zehrfeld; Gerald Hensel; Kerstin Löschcke; Rainer Krahl; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-25       Impact factor: 4.553

9.  Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Authors:  M Offidani; L Corvatta; L Maracci; A M Liberati; S Ballanti; I Attolico; P Caraffa; F Alesiani; T Caravita di Toritto; S Gentili; P Tosi; M Brunori; D Derudas; A Ledda; A Gozzetti; C Cellini; L Malerba; A Mele; A Andriani; S Galimberti; P Mondello; S Pulini; U Coppetelli; P Fraticelli; A Olivieri; P Leoni
Journal:  Blood Cancer J       Date:  2013-11-22       Impact factor: 11.037

Review 10.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.